GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

gsk.com/en-gb/media/press-releases/gsk-and-hengrui-pharma-enter-agreements

Issued: London, UK
For media and investors only
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
- Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development…

This story appeared on gsk.com, 2025-07-28 14:14:46.626000.
The Entire Business World on a Single Page. Free to Use →